Skip to main content
. 2021 Jan 19;4:82. doi: 10.1038/s42003-020-01606-9

Fig. 7. Schematic diagram illustrates the clinical feasibility of combining biomaterials with modRNA-treated BMSCs for bone repair.

Fig. 7

Our platform favors an autologous cell therapy approach where human BMSCs are isolated from bone marrow of ilium and expanded in vitro. BMSCs are then engineered with modified mRNAs and are inoculated into scaffolds, which are implanted into human bone (cranial) defect sites.